Details for New Drug Application (NDA): 021178
✉ Email this page to a colleague
The generic ingredient in GLUCOVANCE is glyburide; metformin hydrochloride. There are twenty drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the glyburide; metformin hydrochloride profile page.
Summary for 021178
Tradename: | GLUCOVANCE |
Applicant: | Bristol Myers Squibb |
Ingredient: | glyburide; metformin hydrochloride |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 1.25MG;250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Jul 31, 2000 | TE: | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 2.5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Jul 31, 2000 | TE: | RLD: | Yes |
Profile for product number 003
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Jul 31, 2000 | TE: | RLD: | Yes |
Expired US Patents for NDA 021178
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bristol Myers Squibb | GLUCOVANCE | glyburide; metformin hydrochloride | TABLET;ORAL | 021178-001 | Jul 31, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Bristol Myers Squibb | GLUCOVANCE | glyburide; metformin hydrochloride | TABLET;ORAL | 021178-003 | Jul 31, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Bristol Myers Squibb | GLUCOVANCE | glyburide; metformin hydrochloride | TABLET;ORAL | 021178-002 | Jul 31, 2000 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription